La FDA lance le programme ImportShield pour renforcer la surveillance des aliments, des médicaments et des dispositifs médicaux importés.

Résumé de la mise à jour

Le FDA ImportShield Program centralizes the agency’s import review operations by consolidating regional teams into a single national framework. This unified approach now applies to all FDA-regulated imports at every U.S. port of entry, replacing previously fragmented regional reviews.

Through upgraded technology platforms, FDA investigators can access multiple data sources more quickly during admissibility decisions, supporting real-time risk management. The program enables nationwide alerts for high-risk products, including counterfeit drugs et contaminated foods, allowing faster and more consistent responses across ports.

The FDA also reported that monthly import processing capacity has increased, while the staff hours required for import reviews have decreased, reflecting improved operational efficiency. Importantly, consistent enforcement measures are now applied across all FDA-regulated product categories.

Date d'entrée en vigueur

La version mise à jour FDA ImportShield Program requirements have applied to all imports of FDA-regulated products entering U.S. ports since August 2025.

Pourquoi c'est important

The ImportShield Program provides greater regulatory clarity and consistency by standardizing import reviews nationwide. Enhanced digital integration and centralized screening improve efficiency while supporting proactive identification of high-risk imports, helping the FDA manage rising import volumes without imposing unnecessary administrative burden.

À qui cela s'adresse-t-il ?

Cette mise à jour est particulièrement pertinente pour Regulatory Affairs, Quality Assurance, Compliance, Supply Chain, and IT teams, as well as organizations responsible for importing FDA-regulated products into the U.S. market.

Prochaines étapes

Importers should review current import and documentation procedures to ensure alignment with the centralized FDA review process. Cross-functional teams should assess readiness for real-time data requests, renforcer traceability practices, and update internal training to reflect the new import oversight framework.

As import oversight becomes increasingly centralized and data-driven, organizations need timely visibility into regulatory expectations across borders. RegASK is a leading agentic AI regulatory intelligence and workflow orchestration platform that empowers global organizations in highly regulated sectors, including consumer products and life sciences, to proactively navigate complex regulatory landscapes. By combining advanced IA agentique with experts in the loop, RegASK delivers timely predictive actionable insights and end-to-end automation, helping teams stay aligned with evolving FDA import controls while mitigating compliance risk. En savoir plus ou réservez une démo maintenant. 

FAQ

What is the FDA ImportShield Program?

Le FDA ImportShield Program (FISP) is a centralized national framework launched by the FDA to modernize and strengthen the review of imported FDA-regulated products at U.S. ports of entry.

When did the FDA ImportShield Program take effect?

The program became active in August 2025, with initial results announced on January 21, 2026.

Which products are covered under ImportShield?

La réglementation affecte importateurs des secteurs de l'alimentation, de la pharmacie et des dispositifs médicaux, notamment celles qui traitent des marchandises soumises à restrictions spécifiées.

How can RegASK support companies affected by FDA ImportShield?

RegASK helps organizations monitor FDA import-related updates, assess compliance impacts, and streamline regulatory workflows using agentic AI-driven intelligence, supporting proactive readiness for centralized and real-time import scrutiny.